Industry news that matters to you.  Learn more

Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study

A novel biomarker for rheumatoid arthritis (RA) has significant potential to help physicians better identify early-stage disease, when treatment can often arrest further disease progression and disability, according to a new study in The Journal of Rheumatology.

Augurex Announces Exclusive License Agreement with Quest Diagnostics for the Development of Arthritis Biomarker 14-3-3 eta as a Testing Service in the U.S.

Augurex Life Sciences Corp. recently announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex’s rheumatoid arthritis (RA) 14-3-3 eta biomarker. Quest Diagnostics is the world’s leading diagnostic testing company, and serves approximately half of the physicians and hospitals in the United States. Quest Diagnostics expects to launch the service in 2013. Additional terms were not disclosed.